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Abstract. CD 105 is a receptor for transforming growth factor-6 
but it is also considered to be involved in cellular functions 
such as cell adhesion and migration. Using CD 105 transfected 
rat myoblasts, we have investigated the role of CD 105 in 
cell adhesion, spreading, growth and migration. CD 105 trans­
fected myoblasts expressed abundant CD105, which was 
preferentially located within focal adhesion sites. These cells 
took on a bipolar morphology whereas mock cells remained 
polygonal or rounded, and when wounded, CD 105 expressing 
cells realigned their long axis prior to migrating and migrated 
as a cohort of cells. CD105 expression promoted cellular 
attachment, spreading, survival and growth in serum-free 
conditions and each of these parameters could be inhibited by 
a RGD-containing peptide but not a RAD-containing peptide. 
Mock-transfected cells could not attach, spread or grow under 
these conditions. Attachment, spreading and growth in CD 105 
expressing cells could be promoted by the addition of a mono­
clonal antibody against CD105. Expression of CD105 resulted 
in the phosphorylation of JNK1 but had no effect on 61 integrin 
expression. From this preliminary study, we conclude that in 
addition to acting as a transforming growth factor-8 receptor, 
CD 105 has an important role in cell adhesion, migration and 
survival. 
Introduction 
CD 105 (endoglin) is an angiogenic mediator predominately 
expressed by endothelial cells (EC) but also by activated 
macrophages, some stromal cells and vascular smooth muscle 
cells (1-5). It is located within the cell membrane as a 180 kDa 
homodimeric transmembrane glycoprotein whose external 
domain binds transforming growth factor-B (TGFB) isoforms 1 
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and 3 with a high affinity and whose transmembrane and 
intracellular domains share a 71% sequence homology to 
betaglycan (6). CD 105 has been linked with cell migration, 
e.g. it is expressed during the transition from polarised un­
differentiated to non-polarised intermediate cytotrophoblasts 
as the cells align in columns to invade the uterus (7). CD105 
production in cytotrophoblasts occurs in parallel with the 
expression of the fibronectin receptor, a561 integrin and 
evidence suggests that there may be an interaction between 
the two. 
CD 105 plays important roles in cardiovascular develop­
ment. It is markedly up-regulated in endocardial cushion 
mesenchyme during valve formation in human embryos at 5-8 
weeks of gestation (8), and is highly expressed on ECs during 
angiogenesis (9-14). The importance of CD 105 expression in 
vasculogenesis can also be seen in CD105 knockout mice 
where the animals die in utero at 10-11.5 days because of 
abnormal blood vessel formation (4,15). CD 105 is also the 
target gene for the human, dominant vascular disorder -
hereditary haemorrhagic telangiectasia 1 (16). 
How CD 105 functions in these diverse physiological and 
pathological processes is not fully understood. Although it is 
an important component of the TGF8 receptor signalling 
complex, it is unlikely that its sole function is to bind TGF6. 
Indeed, even though there is a 100-fold excess of CD 105 to 
the TGF6 receptor II on the surface of normal ECs, only 1% 
of the total CD105 molecules are able to bind TGF61 (6). 
It may act via interaction with other membrane receptor 
proteins, such as TGF6 receptors or directly associate with 
intracellular proteins such as focal adhesion kinase (FAK) or 
adaptor proteins. Overexpression of CD105 in rat myoblasts 
and myelomonocytic cells substantially decreases the ability 
of TGF61 to inhibit cellular proliferation and to stimulate 
fibronectin and plasminogen activator inhibitor 1 synthesis, 
indicating that CD 105 can modulate specific responses to 
TGFB1 (1,17). CD105 is a RGD-containing integral membrane 
protein and as such it may act as a counter-receptor for one 
or more members of the integrin family (18). When human 
umbilical vein EC (HUVEC) monolayers were pre-treated 
with monoclonal antibodies (mAbs) to CD105, a 5- to 10-fold 
increase in adhesion of non-adherent U937 cells to HUVECs 
was observed (18). A fibronectin hexapeptide, containing RGD, 
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but not the corresponding RGE control peptide, antagonised 
the enhancement of adhesion induced by the CD 105 mAbs, 
suggesting that the signal is triggered by CD 105 through its 
RGD structure (18). Therefore, CD 105 may act through its 
RGD or other structure(s) to affect cell attachment, spreading 
and migration. 
Here, utilising CD 105 transfected rat myoblasts, we 
demonstrate that CD 105 is preferentially localised at focal 
adhesion sites. CD 105 expression resulted in morphological 
changes and directional cell movement. Furthermore, in 
the absence of serum, CD 105 promoted cell spreading. Un­
expectedly, anti-CD105 mAb, E9, markedly enhanced cell 
spreading, which could be blocked by RGD but not RAD-
containing peptides. Lastly, overexpression of CD105 led to 
phosphorylation of JNKl. We propose that the cell survival 
mediated by CD 105 works through the integrin related FAK/ 
Cas/Crk/Rac/MKK4/JNK pathway. 
Materials and methods 
Stable rat myoblast transfectants. Rat myoblast transfectants, 
expressing CD 105 were established by co-transfecting PcEXV 
Endo S and psV2neo as described by Letamendia et al (17). 
Transfection with psV2neo alone yielded cells which did not 
express CD105 - mock transfectants (19). All transfectants 
were maintained in a humidified incubator in 5% C02 at 37°C 
in DMEM (Sigma) supplemented with 10% foetal bovine 
serum (FBS, Gibco BRL), and 400 jig/ml G418 (Sigma) unless 
stated below. Media were changed every third day. 
Human dermal microvascular endothelial cells (HDMECs). 
HDMECs (Clonetics, San Diego, CA) were cultured in 
medium MCDB 131 supplemented with 10% FBS, 100 u.g/ml 
penicillin, 100 |ig/ml streptomycin, 2 mM L-glutamine (all 
Gibco) and 10 ng/ml epithelial growth factor (Sigma). Cells 
were maintained at 37°C in a humidified incubator at 5% 
C02 as above. 
Wounding assays for cell migration. Mock and CD105 
expressing rat myoblast transfectants were seeded at 5xl05 
cells/well in 12-well plates. This concentration produced 
rapid confluency and after 24 h, the confluent cell monolayer 
was wounded with a 1 ml (blue) plastic pipette tip, generating 
a linear wound, -15 cells wide. The entire cultures were rinsed 
3 times with PBS to remove cellular debris; fresh medium 
was added and they were cultured under standard conditions. 
The wound areas were inspected regularly during the next 24 h 
under phase contrast microscopy and photomicrographs were 
taken using a Leitz Diavert microscope equipped with a Wild 
Photoautomat MPS45 system. The distance and direction of 
cell movement and the morphology of the cells were evaluated. 
Cell attachment and spreading assay. The effect of CD 105 on 
cell attachment and spreading was evaluated by inoculating 
cells onto tissue culture dishes for 2 or 24 h respectively. 
Mock and CD 105 expressing rat myoblast transfectants 
were seeded in 12-well plates and when -60% confluent were 
harvested in one of three ways: i) scraping followed by 
repeated pipetting of the cells (20); ii) treatment with EDTA 
(0.02%, Sigma)/trypsin (0.05%, Gibco) solution followed by 
washing in 0.2% soybean trypsin inhibitor; or iii) treatment 
with EDTA alone. After harvest the cells were plated out in 
96-well plates at 104 cells/well for cell attachment or in 12-well 
plates for cell spreading. 
To examine the effect of the anti-CD105 mAb E9 on cell 
attachment, spreading and proliferation, mock and CD 105 
expressing rat myoblasts were inoculated into wells in serum-
free medium already supplemented with anti-CD 105 mAb E9 
(1 or 10 (xg/ml) (12) or control mAb of the same isotype as 
mAb E9 (Santa Cruz Biotechnology, Inc.). Cell morphology 
was recorded by examination under a phase contrast micro­
scope for 24 h. 
In blocking assays for attachment and spreading, a poly­
peptide RGD sequence containing (GLY-ARG-GLY-ASP-
SER-PRO-LYS) (Sigma), or a RGD mutant polypeptide - RAD 
sequence containing (GLY-ARG-ALA-ASP-SER-PRO-LYS) 
(Sigma) was added into the medium. 
Cells were fixed for 30 min with 100% methanol (BDH) 
and then washed once with PBS. The total number of cells 
attached and the percentage of spread cells were counted in 
at least three random fields, in each of 3 wells, using the xlO 
objective on the phase contrast microscope. A spread cell 
was characterised as one having a clearly visible ring of cyto­
plasm around the nucleus. 
Western blot analysis. Mock transfected and CD105 expressing 
rat myoblasts were grown to near confluence as described 
above and harvested in EDTA/trypsin in PBS, washed with 
PBS and pelleted by centrifugation. For CD105 analysis, 10 [il 
total cell lysis buffer [containing 20 mM Tris-HCl, pH 7.5, 
150 mM NaCl, 10% (v/v) glycerol, 1% Triton X-100 (all 
BDH), 2 mM EDTA, 100 \iM Na3V04, 1 mM PMSF, 10 fig/ml 
each of aprotinin, leupeptin and pepstatin (all Sigma)] was 
added to 2xl06 cells. For p-JNK analysis, myoblasts were 
cultured in serum-free medium for 24 h before adding 100 txl 
total lysis buffer. 
The protein concentration in the cell lysates was measured 
by a Bio-Rad protein assay as per the manufacturer's 
instructions and 50 u.g of protein was subjected to SDS-PAGE 
on 7.5% polyacrylamide gels under reducing (for P-JNK) or 
non-reducing (for CD 105) conditions. Proteins were electro-
phoretically transferred to PVDF membrane (Millipore Corp., 
Bedford, MA). The blots were blocked with PBS-Tween buffer 
containing 5% non-fat milk powder for 2 h and then incubated 
with anti-CD105 mAb E9 or anti-p-JNK mAb Sc6254 (0.2 u.g/ 
ml, Santa Cruz Biotechnology, Inc.) at 4°C overnight, followed 
by an HRP-conjugated rabbit anti-mouse IgG (1:2000 dilution, 
Dako) at room temperature. The membrane was developed 
using an enhanced chemiluminescence (ECL) detection system 
(Amersham Pharmacia Biotech). 
Evaluation of loading controls was performed by stripping 
the membrane with 2% 2-mercaptoethanol-PBS solution, and 
incubating the blots with primary rabbit anti-total JNK Ab 
(0.2 |U,g/ml, Sc571, Santa Cruz Biotechnology, Inc.) or rabbit 
anti-actin Ab (0.2 ng/ml, Sigma), acting as loading controls 
for p-JNK and CD 105 respectively and then incubating with 
the HRP-conjugated goat anti-rabbit Ab, prior to ECL. 
Flow cytometry analysis. Cell surface expression of 61 integrin 
on transfected rat myoblasts was quantified by flow cytometry 
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Figure 1. Expression of CD 105 by CD 105 transfected cells and cellular 
morphologies at confluence and after wounding. (A), Immunoblot showing 
the presence of a 160 kDa band corresponding to S-CD105 from CD105 
expressing cells. Mock-transfected cells were negative. Actin was used as a 
control for loading. (B), Mock-transfected cells retain a polygonal/rounded 
morphology whereas, (C) CD105 expressing cells are bipolar and appear to 
align into parallel cords. (D), Twenty-four hours following wounding, mock-
transfected cells have migrated into the wound in a random manner whereas, 
(E) CD 105 expressing cells have migrated further and as a cohort across the 
wound. *The wound location. Scale bars, 50 \im (A and B); 40 (im (C and D). 
using the method of Pichard et al (21). Briefly, mock and 
CD 105 expressing rat myoblast transfectants were seeded in 
35 mm dishes in media and incubated for 48 h. The cells were 
detached on ice in 1 mM EDTA/PBS solution for 30 min 
(Sigma), a single cell suspension was then obtained by gently 
pipetting the cells. The cells were washed, treated with primary 
rabbit anti-61 integrin antibody in PBS (2 |ag/ml, Chemicon 
International, Inc., Temecula, CA) for 1 h on ice and then 
washed twice with cold PBS. The cells were incubated with 
a secondary, FITC conjugated swine anti-rabbit antibody 
for 45 min at 4°C (1:40 dilution; Dako) and processed for 
flow cytometry using a FACScan flow cytometer (Becton 
Dickinson). 
Indirect immunofluorescence. Mock transfected and CD 105 
expressing rat myoblasts and HDMECs were cultured in 8-weIl 
chamber slides at lxlO4 cells/ml (Lab Tek, Naperville), and 
incubated overnight. On the following day, the cells were 
washed with PBS and fixed with cold 100% methanol for 
10 min. After blocking with 10% rabbit serum (Sigma) for 
30 min, cells were incubated with the anti-CD105 mAb, E9, 
(2 |J.g/ml) for 1 h, chambers were washed with PBS and treated 
with FITC conjugated, rabbit anti-mouse-IgG (at 1:50 dilution, 
Dako) for 45 min. The stained preparations were mounted 
Figure 2. Distribution of CD 105 on rat myoblasts and HDMECs. Cells were 
exposed to anti-CD 105 antibody, mAb E9 and then a secondary FITC 
conjugated antibody. (A), CD105 expressing cells show localisation of 
CD 105 at focal adhesion sites with some accumulation around the nucleus. 
(B), Mock-transfected cells are negative for CD105. (C), HDMEC which are 
known to produce CD105 also have some localisation to focal adhesion sites. 
(D), Negative controls. Scale bar, 1.4 fim. 
with Citifluor (Citifluor Ltd., London), and coverslips were 
sealed with nail varnish then examined in a Leitz fluorescence 
microscope. 
Results 
Alteration in cell morphology and migration due to expression 
of CD105. All experiments were performed at least 3 times 
with similar results. Western blot analysis showed that CD105 
transfectants displayed high expression of CD 105, whereas 
mock cells were negative (Fig. 1A). At low cell density, mock 
transfectants were polygonal in morphology and tended to 
grow in small clusters, this polygonal morphology persisted 
at confluence with some evidence of multilayering and cell 
rounding (Fig. IB). In contrast, CD 105 expressing cells took 
on a bipolar fibroblastic morphology and tended to grow 
individually. At confluence these cells remained bipolar, 
often aligning in a head-to-tail fashion making parallel cords 
(Fig. 1C). The addition of a neutralising antibody to TGF81 
(10 Jig/ml; R&D Systems) had no effect on cell morphology 
(data not shown) indicating that morphology was not due to 
the presence of TGFB1. 
To investigate the effect of CD 105 expression on cell 
migration, wounding assays were set up. Briefly, mock trans­
fectants and CD 105 expressing cells were seeded in un-coated 
tissue culture dishes in DMEM containing 10% FBS and G418 
(400 u,g/ml) and a wound was made using a sterile pipette 
tip. Over a period of 24 h, mock cells moved into the wound 
in a random fashion (Fig. ID), whereas CD 105 expressing 
cells appeared to realign their long axis and migrate across 
the wound in a cohort of aligned cells (Fig. IE). 
Examination of immunofluorescence stained preparations 
showed that the distribution of CD 105 in transfected rat myo­
blasts was not uniform. Using a fluorescent antibody to CD105, 
regions of high intensity fluorescence were observed at focal 
adhesion sites, most often on both apexes of polarised cells in 
CD 105 expressing cells (Fig. 2A). A similar staining pattern 
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Figure 3. CD 105 influences cell attachment and spreading. Cells were grown 
in serum-containing medium then harvested and plated out in serum-free 
medium. (A), When detached using EDTA solution, CD105 expressing cells 
were able to spread in serum-free media over a 24-h period whereas mock cells 
could not. Very few cells were able to spread if detached using EDTA/trypsin 
solution. (B), Addition of anti-CD105 antibody E9 allowed CD105 cells to 
spread within 24 h even if detached with EDTA/trypsin. E9 antibody exhibited 
a concentration-dependent effect. Mock-transfected cells did not spread. (C), 
CD105 expressing cells, detached by EDTA/trypsin and grown in the presence 
of E9 antibody were able to proliferate and reach confluence by 96 h. Mock-
transfected cells did not grow (data not shown). Data were obtained from 
triplicate readings from three separate experiments for each assay. *SEM, 
p<0.01 analysed by a one-way ANOVA followed by a Duncan's test. 
was observed in HDMEC cells, which are known to express 
CD105 (Fig. 2C). In contrast, mock-transfected cells did not 
demonstrate any fluorescent staining (Fig. 2B). 
CD 105 expression had no effect on the morphology or the 
ability to adhere in the non-adherent U937 cell line (data not 
shown). 
The effect of CD105 on cell attachment and spreading. In 
serum-free media, CD 105 expressing cells (harvested either 
by cell scraping or by EDTA/PBS solution) were able to attach 
and spread within 24 h, however, mock-transfected cells did 
Figure 4. CD 105 expression is associated with JNK1 phosphorylation but not 
Bl integrin up-regulation. (A), SDS-PAGE of cell lysates followed by ECL 
detection demonstrates the presence of phosphorylated JNK1 in CD 105 
expressing cells but not in mock-transfected cells. (B), CD105 expressing 
and mock-transfected cells were incubated with a polyclonal rabbit anti-Rl 
integrin antibody and processed for flow cytometry. Cells were incubated 
with non-immune rabbit serum for controls. There was no difference in Bl 
integrin expression between CD105 expressing and mock-transfected cells. 
Data were obtained form triplicate reading from three separate experiments. 
Data were analysed by a one-way ANOVA followed by a Duncan's test. 
not spread or grow (data not shown). Exposure to an RGD-
containing peptide inhibited CD 105 cell spreading but exposure 
to a RAD-containing peptide had no effect (data not shown). 
Very little cell spreading was observed if, prior to plating out, 
mock-transfected or CD 105 expressing cells were harvested 
with an EDTA/trypsin solution (Fig. 3A). This inability to 
spread could be reversed in CD 105 expressing cells but not 
in mock cells by the addition of the anti-CD 105 antibody, E9 
in a concentration-dependent manner (Fig. 3B). A control 
antibody of the same isotype as E9 had no effect on either 
cell (data not shown). CD 105 expressing cells were able to 
grow and proliferate in serum-free media containing E9 for 
>1 week and reach confluence (Fig. 3C). Once again, cell 
attachment and spreading in the presence of E9 was anta­
gonised by a RGD but not a RAD-containing peptide (data 
not shown). 
CD105 and cell signalling. Mock-transfected and CD105 
expressing cells were grown to -80% confluency in serum-
containing medium and then transferred to serum-free medium 
for 24 h, when the cells were washed, harvested and lysed. 
Immunoblotting analysis demonstrated that overexpression 
of CD105 was accompanied by phosphorylation of JNK1 
(Fig. 4A) whereas flow cytometry showed no alteration in 
expression of 61 integrin (Fig. 4B). 
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Figure 5. Diagrammatic representation of cell signalling pathways in CD105 expressing cells. CD105 could interact with integrins via its RGD sequence (left 
side) or directly with intracellular adapter proteins such as paxillin or P130Cas (right side) in order to influence cell morphology and survival. Adapted from 
refs. 23,35,45. 
Discussion 
CD 105 is an important component of the TGFB receptor 
complex but only approximately 1% of the total number of 
CD 105 molecules are able to bind TGF61 in ECs (6). This 
suggests that CD 105 has other functions. In this report we 
demonstrate that CD105 expression is linked to cell adhesion, 
spreading and growth, it influences cellular morphology and 
may be localised to focal adhesion sites to aid migration. In 
addition, we show that CD 105 expression results in phospho­
rylation of JNK1 - an indicator of integrin activation (22,23). 
Mock-transfected cells could adhere and spread to take on 
a polygonal morphology and grew in clusters when grown in 
serum-containing medium. In serum-free medium, these cells 
did not spread or grow. CD 105 expressing cells also attached 
and spread in serum-containing medium where they grew as 
individual cells, took on a typical, bipolar, fibroblastic morpho­
logy and formed head-to-tail alignments. The expression of 
CD 105 allowed these cells to continue to attach and retain 
their fibroblastic morphology in serum-free medium in the 
absence of any TGFB1. CD 105 expressing cells were unable 
to move in a random manner following wounding, they 
manifested directionally persistent motility, which may be 
related to the local accumulation of CD 105 in focal adhesions. 
The morphological changes caused by overexpression of 
CD 105 in rat myoblasts are similar to those found in mouse 
fibroblasts overexpressing CD105 (24), where the cells were 
maintained on fibronectin or collagen-coated culture dishes. 
The non-random distribution of CD 105 reported here is 
consistent with a recent report that prostate cells transfected 
with CD105 showed localisation of CD105 in adhesion sites 
(25). These authors also noted co-localisation of CD105 with 
actin in the adhesion sites. Since cell morphology is determined 
mainly by its intracellular organisation of cytoskeletal actin and 
influenced by focal adhesions (26), it is reasonable to conclude 
that CD105 affected cell morphology in myoblasts, in this 
report, by interacting with molecules in focal adhesion sites. 
Cellular morphology is controlled by the interaction of 
integrins with the protein components of focal adhesion 
complexes and thus, the actin cytoskeleton, producing the 
bipolar, fibroblastic shape (27-29). Activation of integrins 
occurs via a RGD-containing ligand binding to the extracellular 
domain of the integrin. In this report, CD105 expression did 
not alter the gene expression level of 61 integrin, which 
suggests that CD 105 may be activating the existing integrin via 
its RGD sequence on the extracellular portion of the molecule 
or CD 105 may activate other focal adhesion components 
directly - as shown diagrammatically in Fig. 5. CD105 has 
previously been proposed as a counter-receptor for one or 
more members of the integrin family (18). Once activated, 
integrins can mediate different pathways regulating signal 
transduction through a focal adhesion kinase (FAK) (30,31) 
or FAK independent Cas/Crk/Rac pathway (26) and organise 
the actin cytoskeleton through the small Rho-GTPase family 
(32). The Rho family of GTPases serve as molecular switches, 
transducing signals from the extracellular environment to elicit 
cellular responses such as changes in gene expression, morpho­
logy and migration (33). 
Other cell receptors are known to activate integrins via 
the RGD sequence, e.g. the RGD sequence of the P2Y2 
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nucleotide receptor (P2Y2R) interacts with av63 integrin and 
is required for G0-mediated signal transduction (34). In this 
report we have demonstrated that JNK is phosphorylated in 
CD105 expressing cells. Fig. 5 shows that JNK phosphorylation 
occurs after integrin activation and may occur via the FAK/ 
Cas/Crk/Rac/Pakl/MKK4/JNK pathway (35). Therefore we 
suggest that integrins are involved in CD105-related cellular 
responses. JNK activity is known to be elevated upon integrin 
aggregation (22,36). Activation and phosphorylation of 
P130Cas has been linked to directionally persistent movement 
(37) as exhibited here by CD 105 expressing cells following 
wounding. Directional cell movement plays important roles 
during wound healing, angiogenesis and immune function 
(38). The movement of ECs, smooth muscle cells and macro­
phages, all of which have significantly increased levels of 
CD105 (1,2,39-41), may be important in these processes. 
Cell spreading is closely linked to cell survival and growth 
(42,43). The cell spreading observed when CD 105 expressing 
cells were grown in serum-free medium was directly linked 
to the presence of the RGD sequence in the CD 105 since it 
could be antagonised by a RGD peptide but not a RAD peptide. 
Mock-transfected cells, which did not express CD105, were 
considerably easier to detach from the tissue culture surface, 
even in the presence of serum. The anti-CD105 mAb, E9, 
markedly promoted cell spreading and growth of CD 105 
expressing cells on uncoated plastic dishes in serum-free 
medium. Once again, this effect was blocked by a RGD but 
not a RAD-containing peptide. Anti-CD 105 mAbs (44G4 
and 29-G8) have been reported to stimulate the proliferation 
of foetal bone marrow stromal cells in medium with 10% 
FCS (44). Treatment of HUVEC monolayers with a panel of 
anti-CD 105 mAbs has been observed to result in a 5- to 10-
fold increase in adhesion of U937 cells to HUVECs. This 
adhesion can be inhibited by a RGD-containing hexapeptide 
(18). The adhesion is believed to be due to interactions 
between integrin and the RGD sequence of the CD 105, a 
similar observation to that reported here. The exact role 
played by anti-CD 105 antibodies remains unclear but it is 
possible that the binding of the anti-CD 105 mAb to CD 105 
leads to a conformational change in CD 105 which then 
allows the RGD sequences on the CD105 extracellular 
domain to fully bind and activate Bl integrin. 
CD 105 may be able to activate the actin cytoskeleton 
through a pathway which does not involve integrins. The 
integrin subunit 131 is a transmembrane protein which consists 
of a large extracellular domain, a single transmembrane stretch, 
and a short intracellular cytoplasmic domain (36). CD 105 is 
also a transmembrane glycoprotein with a large extracellular 
domain and a short intracellular cytoplasmic domain. The 
structure of CD105 is similar to Bl integrin. Therefore CD105 
may be able to regulate the organisation of the actin cyto­
skeleton by interacting directly with the Rho-family of proteins 
and adaptor proteins, such as paxillin and P130Cas and as 
such influence cell morphology (Fig. 5). 
In summary, overexpression of CD 105 in rat myoblasts 
leads to a transition of cell morphology from a polygonal shape 
to a fibroblast-like elongated form. An immunofluorescence 
study demonstrated that CD 105 resided in the focal adhesion 
complex. CD 105 expressing cells exhibited cell polarity. The 
cells were able to attach and spread in serum-free medium 
and anti-CD105 mAb, E9, enhanced this effect. Spreading was 
blocked by the addition of a RGD peptide. We suggest that 
CD 105, in addition to having a role as a TGFB receptor, has a 
major role in influencing cell adhesion, migration and survival. 
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